The Law Firm of Motley Rice LLC

Pfizer, maker of Celebrex, issued a press release December 17, 2004, indicating that Celebrex may have increased the risk of heart attack and stroke in patients who took the drug as part of a long-term study. The study, sponsored by the National Cancer Institute, was halted due to data indicating Celebrex patients developed over two times the number of cardiovascular events than other patients not taking Celebrex.

Celebrex, a member of a new category of drugs called "Cox inhibitors", has provided pain relief and anti-inflammatory effects for millions of pain sufferers. The advertised advantage of this new class of drugs over the traditional non-steroidal anti-inflammatory drugs, such as aspirin, ibuprofen and naproxen, is there are supposedly fewer gastrointestinal problems occurring during treatment with Cox inhibitors.

If you or someone you know, has been injured by taking Celebrex, you may be entitled to compensation. If you would like to explore your legal rights, please provide the following information and it will be forwarded to a Motley Rice pharmaceutical attorney.

Name:(required)

Email Address:

State of Residence:

Daytime Phone:(required)

Evening Phone:

Best Time to Call:

Please provide the following information to allow us to better serve you:

1. Approximate dates of Celebrex use:

From To

2. What dosage did you take per day:

3. Was the dosage ever changed? To what?

4. When were you first aware of any medical problems related to Celebrex?

5. Did you experience any of the following conditions related to Celebrex?

Heart Attack
Stroke
Deep Vein Thrombosis
Blood Clots
Abnormal bleeding
Pulmonary Embolism
Death

Other condition:
(Please explain)

6. Did your physician provide that your diagnosis could be related to Celebrex?

Yes No